Kalaris Therapeutics, Inc. (KLRS) Fair Value 2026

KLRS · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 7 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-07-15, Kalaris Therapeutics, Inc. (KLRS) trades at $4.82, approximately 400% above CirclFi’s Bayesian DCF fair value of $0.96. QOC: 4.3/10. Value Trap Risk: 39/100 (LOW). 7/13 models active.

Key Facts

Ticker
KLRS
Price
$4.82
Quality Score
4.3/10
Value Trap Risk
39/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

Is Kalaris Therapeutics, Inc. (KLRS) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Kalaris Therapeutics, Inc. (KLRS) appears overvalued as of : the median of 7 independent fair value estimates is $2.17, 54.9% below the current price of $4.82. Estimates range from $0.16 to $5.28. KLRS scores 4.3/10 on fundamental quality and 39/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Kalaris Therapeutics, Inc. Stock in 2026? →

Valuation Matrix

7 Intrinsic Value Models vs. Current Price ($4.82)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.96 -80.0%
CUCE Ensemble
Low Conviction
 $2.17 -54.9%
First Chicago
Low Conviction
 $4.45 -7.6%

Unlock the Full Matrix

Access 4 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is Kalaris Therapeutics, Inc. (KLRS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kalaris Therapeutics, Inc.'s intrinsic value is estimated at $2.34. Trading at its current price of $4.82, the valuation engine raises significant caution: 6 of 7 models flag downside risk, projecting an average implied return of -51.5%. Notably, Sentiment SOTP sees the most upside at +9.6% (fair value: $5.28), while ML-RIV is the most conservative at -96.6% ($0.16). The spread between these extremes — +106.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About KLRS?

7 of 13 models are currently active for KLRS. Of these, 1 model suggests upside while 6 models suggest overvaluation. The Bayesian DCF estimates KLRS's intrinsic value at $0.96, implying -80.0% downside from the current price. See which stocks rank higher →

How Does KLRS Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, KLRS ranks #108 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Kalaris Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is KLRS a Value Trap?

CirclFi's Value Trap algorithm assigns KLRS a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Kalaris Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Kalaris Therapeutics, Inc. scores 4.3 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +106.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KLRS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across KLRS's 7 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kalaris Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Kalaris Therapeutics, Inc.

What is Kalaris Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Kalaris Therapeutics, Inc. (KLRS) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.96. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KLRS overvalued or undervalued right now?

At $4.82, 1 of 7 active models suggest KLRS may be undervalued, while 6 indicate potential overvaluation. The median of all 7 fair value estimates is $2.17, 54.9% below the current price of $4.82 — a consensus view that KLRS is overvalued. The assessment depends on which methodology best fits Kalaris Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 4.3 mean for KLRS?

Kalaris Therapeutics, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on KLRS?

CirclFi analyzes KLRS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Is KLRS a value trap in 2026?

Kalaris Therapeutics, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Kalaris Therapeutics, Inc. (KLRS) has a median fair value of $2.17 — 54.9% below the current price of $4.82 — as of 2026-07-15.” Source: circlfi.com/stock/KLRS/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on KLRS.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access